ABSTRACT: Backgro und: The objectives of this study were to elucidate any potential association between a-synuclein pathology and cognitive impairment and to determine the profile of cognitive impairment in multiple system atrophy (MSA) patients. To do this, we analyzed the clinical and pathologic features in autopsy-confirmed MSA patients. Methods: We retrospectively reviewed medical records, including neuropsychological test data, in 102 patients with autopsy-confirmed MSA in the Mayo Clinic brain bank. The burden of glial cytoplasmic inclusions and neuronal cytoplasmic inclusions were semiquantitatively scored in the limbic regions and middle frontal gyrus. We also assessed concurrent pathologies potentially causing dementia including Alzheimer's disease, hippocampal sclerosis, and cerebrovascular pathology. Results: Of 102 patients, 33 (32%) were documented to have cognitive impairment. Those that received objective testing, deficits primarily in processing speed and attention/executive functions were identified, which suggests a frontal-subcortical pattern of dysfunction. Of these 33 patients with cognitive impairment, 8 patients had concurrent pathologies of dementia. MSA patients with cognitive impairment had a greater burden of neuronal cytoplasmic inclusions in the dentate gyrus than patients without cognitive impairment, both including and excluding patients with concurrent pathologies of dementia. Conclusions: The cognitive deficits observed in this study were more evident on neuropsychological assessment than with cognitive screens. Based on these findings, we recommend that clinicians consider more in-depth neuropsychological assessments if patients with MSA present with cognitive complaints. Although we did not identify the correlation between cognitive deficits and responsible neuroanatomical regions, a greater burden of neuronal cytoplasmic inclusions in the limbic regions was associated with cognitive impairment in MSA. V C 2016 International Parkinson and Movement Disorder Society
Multiple system atrophy (MSA) is an atypical parkinsonian disorder characterized by a variable combination of autonomic failure, parkinsonism, cerebellar ataxia, and pyramidal symptoms. 1, 2 Pathologically, glial cytoplasmic inclusions (GCIs), the pathologic hallmark of MSA, are found throughout the brain, especially in striatonigral and olivopontocerebellar systems. 3 Unlike other a-synucleinopathies such as Parkinson's disease (PD) and dementia with Lewy bodies (DLB), dementia (as defined by Diagnostic and Statistical Manual-IV criteria) is not a feature that supports a clinical diagnosis of MSA. 1 A recent position statement by the Neuropsychology Task Force of the Movement Disorders Society MSA study group indicated that cognitive impairment (CI) may be an underrecognized feature in MSA. 4 The frequency of CI ranges from 22% to 37% in autopsy-confirmed MSA. 2, [5] [6] [7] These patients showed a wide spectrum of CI; frontal executive function was most frequently affected, whereas attention, memory, and visuospatial domains were sometimes impaired. 4, 8 The neuropathological underpinnings of CI in MSA are not well defined. Asi et al reported no significant difference in GCIs and neuronal cytoplasmic inclusion (NCI) burden in limbic or cortical regions between MSA with CI (MSA-CI) and MSA without CI (MSA-NC). 9 Recent studies, however, have shown that NCIs rather than GCIs in neocortical or limbic regions are associated with CI in MSA. 5, 7 MSA patients who showed clinical presentations of frontotemporal dementia syndrome had severe limbic NCI. 10, 11 The aims of this study were to determine whether the severity of a-synuclein pathology was associated with CI in MSA and to clarify the profile of CI in MSA. To accomplish our aims, we retrospectively reviewed medical records, including neuropsychological evaluations, and semiquantitatively assessed the burden of GCI and NCI in autopsy-confirmed MSA. To exclude the influence of concurrent pathologies of dementia, we also assessed Alzheimer's-related pathology, hippocampal sclerosis (HpScl), and cerebrovascular pathology.
Methods Subjects
Between 1998 and 2015, 170 patients from the Mayo Clinic brain bank were given a neuropathologic diagnosis of MSA. Of those, 40 patients without any medical records or brain bank questionnaires, 16 patients with only brain bank questionnaires, and 12 patients with medical records evaluated by physicians other than neurologists were excluded from the study. The resulting cohort consisted of 102 patients having medical records with assessments by neurologists or movement disorder specialists. The mean number of medical records available for review was 10.4 (SD, 11.1) in each patient. These cases were received from the following sources: CurePSP: Society for PSP j CBD and Related Disorders (n 5 65), Mayo Clinic Morris K. Udall Center of Excellence for PD (n 5 30), consultation cases (n 5 4), Mayo Clinic Jacksonville Alzheimer's Disease (AD) Research Center (n 5 1), State of Florida AD Initiative (n 5 1), and Mayo Clinic Jacksonville hospital autopsy case (n 5 1). Some of the data on these patients have been presented in previous articles. 6, 12 All brain autopsies were performed with the consent of the legal next of kin or an individual with power of attorney for the patients. Studies using these autopsy samples were considered exempt from human subject research by the Mayo Clinic Institutional Review Board.
Clinical Assessment
Pertinent clinical information derived from the available records or brain bank questionnaires that were filled out by a close family member included sex, age at symptomatic onset, assessment, and death, clinical diagnoses, family history of dementia and parkinsonism, clinical symptoms, and results from cognitive screening measures and neuropsychological assessments. The presence of CI was classified using 2 methods. The first method involved reviewing records for diagnostic impressions of clinicians or patient symptom self-report of impairment. Common subjective indicators of CI included memory loss, forgetfulness, distractibility, word-finding difficulty, difficulty with naming, slowed thinking/bradyphrenia, and executive dysfunction. The second method involved reviewing test scores documented in the record from either cognitive screening tests (eg, the Mini-Mental State Examination, 13 Montreal Cognitive Assessment, 14 or Kokmen Short Test of Mental Status 15 or test scores from comprehensive neuropsychological evaluations. The presence of impairment on neuropsychological tests was classified using cutoff scores (>1.5 SD below the normative mean) commonly accepted in the neuropsychology literature. 16 Patients were considered to have depression if a diagnosis of depression was documented, and the patient was prescribed an antidepressant medication as a primary treatment of depressive symptoms. Symptom onset was defined as the initial presentation of any motor symptom (ie, parkinsonism or cerebellar ataxia) or selected autonomic features (ie, orthostatic hypotension, urinary incontinence, or urinary retention). Based on clinical information, each patient was assigned a clinical subtype: MSA with predominant parkinsonism (MSA-P) or MSA with predominant cerebellar ataxia (MSA-C).
Neuropathological Assessment
All cases underwent a standardized neuropathological assessment for Alzheimer's-type and Lewy-related pathologies. A Braak neurofibrillary tangle stage and Thal amyloid phase were assigned to each case with thioflavin S fluorescent microscopy. 17, 18 Lewy-related pathology was assessed in the cortex, amygdala, basal forebrain, and brain stem and classified as brain stem, transitional, or diffuse Lewy body disease. 19 Immunohistochemistry for a-synuclein (NACP, 1:3000 rabbit polyclonal, Mayo Clinic antibody, FL) 20 was performed on sections of basal forebrain, striatum, midbrain, pons, medulla, and cerebellum to establish a neuropathological diagnosis of MSA 21 as described previously. 12 MSA cases were pathologically divided into 3 types: predominant striatonigral involvement (SND), predominant olivopontocerebellar involvement (OPCA), and equally severe involvement of both systems (mixed). 22 A semiquantitative assessment of GCI and NCI was performed in the following regions: the hippocampus and adjacent cortex, amygdala, cingulate gyrus, deep white matter adjacent to the cingulate gyrus, and middle frontal gyrus. The severity of a-synuclein pathology was graded on a 4-point scale (0 5 absent, 1 5 sparse, 2 5 moderate, 3 5 frequent) as shown in Figure 1 . All slides were reviewed simultaneously by 2 observers (D.W.D. and S.K.). Neuropathological diagnoses of AD, HpScl, and cerebrovascular diseases were based on the established criteria.
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Statistical Analyses
All statistical analyses were performed in SigmaPlot 12.3 (Systat Software, San Jose, CA). A chi-square or Fisher's exact test was performed for group comparisons of categorical data as appropriate. A rank sum test or twas used for analyses of continuous variables as appropriate. The point biserial correlation coefficient was used to assess the correlation between age at symptom onset, assessment, and death and the presence or absence of objective impairment across the cognitive domains. P < 0.05 was considered statistically significant.
Results
Summary of the Cohort
This cohort included 102 patients (63 men and 39 women) with autopsy-confirmed MSA. Median age at symptom onset was 57 years, and median age at death was 65 years. Thirteen patients (13%) had a family history of dementia, and 17 (17%) had a family history of parkinsonism. Of 102 patients, 85 patients (83%) were given an antemortem diagnosis of MSA. The breakdown of the 17 misdiagnosed patients by antemortem diagnosis is as follows: progressive supranuclear palsy (PSP) in 10 (59%), PD in 4 (24%), DLB in 1 (6%), primary progressive aphasia (PPA) in 1 (6%), and M enière's disease in 1 (6%). The clinical MSA phenotypes were MSA-P in 78 patients (76%) and MSA-C in 24 patients (24%). Alzheimer's-type pathology was minimal, with median Braak neurofibrillary tangle stage of I and a Thal amyloid phase of 0. Four patients (4%) had a concurrent pathologic diagnosis of Alzheimer's disease. Lewy-related pathology was observed in 10 patients: 6 were brain stem type and 4 were transitional type. Seven patients (7%) had cerebrovascular pathology, and 2 patients (2%) had HpScl. Thirty-five cases (34%) were pathologically subclassified as MSA-SND, 14 cases (14%) were MSA-OPCA, 51 cases (50%) were MSA-mixed, and 2 cases (2%) could not be classified.
Examination of CI in MSA
Of 102 patients with autopsy-confirmed MSA, 33 (32%) had documented evidence of CI. The median duration between age of symptom onset and age at onset of CI was 2 years, the median duration between symptom onset and assessment by the clinician was 4 years, and the median duration between age at assessment and age at death was 3 years. Only 3 patients (9%) initially presented with CI and motor symptoms simultaneously. One patient developed CI preceding motor symptoms by 1 year. Table 1 summarizes the CI profile characteristics of the 33 MSA-CI patients. Domains of CI -processing speed, attention/executive function, memory, language, and visuospatial -were assigned based on reporting of the following objective CI indicators: comprehensive neuropsychological evaluations (n 5 9, 27%) or cognitive screening tests (n 5 13, 39%) and the reported presence of subjective CI indicators (ie, clinical judgment, diagnostic impressions, and patient self-report; n 5 11, 33%). Cognitive symptoms not reported in the record were designated as a blank (see Table 1 ). To analyze the CI profiles, CI descriptions of the domains noted above were required. Of the 13 patients who received cognitive screening measures, only 6 patients (46%) had reported total scores with no error scores. Therefore, these patients were analyzed using only the subjective CI indicators. Specific CI domains were not documented for 1 MSA-CI patient (patient 22); thus, this patient was excluded from analyses.
The final groups for analyses consisted of objective CI indicators (OBJ; n 5 16) and subjective CI indicators (SUB; n 5 16). The OBJ and SUB groups did not statistically differ with regard to age at symptom onset (59 vs 59, P 5 0.952), age at assessment (64 vs 66, P 5 0.463), or age at death (67 vs 69, P 5 0.525). The 2 groups did not statistically differ with regard to frequency of subjective CI indicators in processing speed (4 vs 8, P 5 0.144), attention/executive function (2 vs 2, P 5 1.000), memory (10 vs 12, P 5 0.446), language (4 vs 2, P 5 0.365), or visuospatial (0 vs 2, P 5 0.144).
Overall, the OBJ group demonstrated deficits primarily in processing speed (n 5 12, 75%) and attention/executive function (n 5 11, 69%), followed by memory (n 5 5, 31%), language (n 5 2, 12%), and visuospatial (n 5 3, 18%). For the 9 patients who received neuropsychological
evaluations, impairments were found predominantly in processing speed (n 5 8, 89%) and attention/executive function (n 5 7, 78%), with less frequent deficits in memory (n 5 1, 11%), language (n 5 2, 22%), and visuospatial (n 5 1, 11%). In the 7 patients who received cognitive screening tests (with error scores), impairments in processing speed, attention/executive function, and memory were observed in 4 patients (44%). Two patients (22%) exhibited visuospatial deficits. No objective language impairments were noted in patients with cognitive screening. There were no statistically significant correlations (point biserial correlation coefficient) between age at symptom onset (all P > 0.135), age at assessment (all P > 0.106), or age at death (all P > 0.201), and the presence or absence of objective impairment in any of the 5 cognitive domains. It is noteworthy that the most common subjective CI identified was in the memory domain. Of the 16 patients in the OBJ group, 10 (63%) had subjective memory impairment. Only 1 patient (6%) and 4 patients (25%) in the OBJ group had objective memory impairment on neuropsychological assessment and cognitive screening, respectively. Another notable finding is that only 3 OBJ patients (19%) had deficits in visuospatial, a cognitive domain commonly impacted in a-synucleinopathies. In contrast, of the SUB group, memory impairment (n 5 12, 75%) was again the most frequent domain of subjective impairment, followed by processing speed (n 5 8, 50%). Only 1 patient (6%) exhibited attention/executive function subjective impairment. Overall, objective cognitive indicators revealed impairments primarily in processing speed and attention/executive function. Although memory impairments were the most frequently affected subjective cognitive domain in MSA, objective indicators were more likely to identify processing speed and attention/executive function deficits than memory deficits.
Comparison Between MSA-CI and MSA-NC Table 2 compares the demographic and clinical features between MSA-CI and MSA-NC. MSA-CI had an older age at onset and death than did MSA-NC (59 vs 57, P 5 0.045; 66 vs 63, P 5 0.029, respectively). Median disease duration was 7 years in both groups. The proportion of women and the frequency of family history of dementia and parkinsonism did not differ between the 2 groups. The frequency of having a clinical diagnosis of MSA was significantly lower in MSA-CI compared with MSA-NC (71% vs 90%, P 5 0.023). Of the 33 patients with MSA-CI, 10 patients were not diagnosed with MSA: PSP in 6, PD in 2, DLB in 1, and PPA in 1 patient. The proportion of clinical MSA phenotypes did not differ between MSA-CI and MSA-NC. Patients with MSA-CI more frequently had depression compared with those with MSA-NC, although this did not reach statistical significance (52% vs 30%, P < 0.066). Table 3 compares pathologic features between MSA-CI and MSA-NC. Median brain weight of MSA-CI was less than that of MSA-NC (1200 vs 1300 g, P 5 0.016). The frequency of Lewy-related pathology, median Braak neurofibrillary tangle stage, and median Thal amyloid phase did not differ between the 2 groups. Four patients with pathologically diagnosed AD, 2 patients with HpScl and 5 patients with significant cerebrovascular pathology developed CI. Taken together, 8 of 33 patients with MSA-CI (patient 11 and patient 30 had multiple pathologies) had at least 1 concurrent pathology of dementia (see Table 1 ), although they were not given antemortem diagnoses of these diseases.
To elucidate any potential association between asynuclein pathology and CI, we compared the burden of NCI and GCI between MSA-CI and MSA-NC. The burden of NCI in the dentate gyrus was greater in MSA-CI than in MSA-NC (1 vs 0, P 5 0.001), but it did not significantly differ in other regions. The burden of GCI did not differ in any regions of interest between the 2 groups. Because a possible association between neocortical Lewy body-like NCIs and CI has been reported, 5 we also assessed the Lewy body-like NCIs in the middle frontal gyrus. Two patients had this pathology ( Supplementary Fig. 1 ), but they were cognitively intact.
Influence of Concurrent Pathology
As mentioned above, 8 patients with MSA-CI had concurrent pathology of dementia (ie, AD, HpScl, and cerebrovascular pathology); therefore, these pathologies rather than a-synuclein pathology might have Cognitive screening total scores were available, but errors unavailable for review. AO, age at onset; AA, age at assessment; AD, age at death; PS, processing speed; Atn, attention; EF, executive functions; Mem, memory; Lan, language; VS, visuospatial processing; CP, concurrent pathology; AD, Alzheimer's disease; HS, hippocampal sclerosis; CV, cerebrovascular pathology; NP, neuropsychological evaluation; CS, cognitive screening; 1 , impairment present; -, impairment absent.
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contributed to their CI. To exclude the influence of these pathologies of dementia, we also analyzed patients with MSA without these pathologies. As shown in Table 4 , age at onset and at death, disease duration, and median brain weight did not significantly differ between the 2 groups. Even after excluding these patients, the burden of NCI in the dentate gyrus was still greater in MSA-CI than in MSA-NC (1 vs 0, P < 0.001). We conclude that the greater burden of NCI in the dentate gyrus is a correlate of CI in MSA patients.
Discussion
In this autopsy-confirmed MSA series, 32% of the patients with MSA had CI documented in the medical record, which is similar to that of other autopsy series. 2, [5] [6] [7] The profile of CI identified in this cohort affected a wide range of domains. The objective deficits found were primarily in processing speed and attention/executive functions. Subjective memory impairments were documented in 66% of the cohort; however, memory deficits were objectively characterized in only 15%. In contrast, the patients with scores on cognitive screening tests performed more poorly on memory recall items compared with evidence of memory deficits from neuropsychological assessments. This finding might be explained by memory problems being a commonly misclassified neurological symptom that is often caused by deficits in cognitive domains unrelated to recall ability (eg, poor encoding because of inattention). 26 The severity of CI identified in this cohort was relatively mild compared with impairments often seen in other a-synucleinopathies such as DLB. It is worth noting that 59% of patients who were given an antemortem diagnosis of a condition other than MSA (10 of 17) had CI. This suggests that patients presenting with parkinsonism and CI tended to be misdiagnosed as other neurodegenerative diseases, namely, PSP, PD, and DLB, even when they had MSA pathology. Our results suggest that although dementia is an exclusion criterion of MSA, MSA should not be excluded from the differential diagnoses in patients with mild cognitive deficits.
We found a trend for increased depression in patients with MSA-CI. Although rating scales or other objective data were unavailable for review, 37% of patients with MSA (38 of 102) had depression, which is almost within the range of other parkinsonian disorders. 27, 28 Patients with depression sometimes mimic patients with dementia (depressive pseudodementia), which is characterized with frontal-subcortical dementia. 29, 30 Thus, MSA-CI in the present study might include some patients with depressive pseudodementia. Given the retrospective nature of this study, however, Data are displayed as median (25th, 75th percentiles). MSA-CI, multiple system atrophy with cognitive impairment; MSA-NC, multiple system atrophy without cognitive impairment. Data are displayed as median (25th, 75th percentiles). GCI, glial cytoplasmic inclusion; NCI, neuronal cytoplasmic inclusion; OPCA, MSA with predominant olivopontocerebellar involvement; SND, MSA with predominant striatonigral involvement.
it was challenging to distinguish between depressive pseudodementia and genuine CI. There are conflicting reports concerning the frequency and severity of CI in MSA-P and MSA-C. 31, 32 These studies were based on the patients with clinically diagnosed MSA. Kawai and colleagues reported that patients with MSA-P showed more severe and widespread cognitive dysfunction than patients with MSA-C. 31 In contrast, patients with MSA-C had more pronounced executive and verbal memory decline than those with MSA-P. 32 Results of our study indicate that both MSA clinical phenotypes (ie, MSA-P and MSA-C) and pathologic subtypes (ie, SND, OPCA, and mixed) were not related to the frequency of CI; however, to assess the association with severity or range of CI, it is necessary to conduct a prospective study.
The neuropathologic analysis revealed that the burden of NCI in the limbic regions was greater in MSA-CI than in MSA-NC. After excluding patients who had concurrent pathologies of dementia, the burden of NCI in dentate gyrus was still greater in MSA-CI. Taken together, severe NCI pathology in the dentate gyrus may correlate with CI in MSA that cannot be explained by AD, HpScl, or cerebrovascular pathology. These results are consistent with a recent study 7 that suggests that frequent globular NCIs in the medial temporal regions is one of the pathologic features of dementia in MSA. Aoki et al proposed a novel variant of MSA, atypical MSA, which is characterized by abundant Pick body-like NCIs in the limbic regions and severe atrophy of the frontal lobe. 10 Patients with atypical MSA show a phenotype of frontotemporal dementia or corticobasal syndrome. 10, 11 The MSA-CI brains evaluated in this study did not have significant cortical atrophy. We assume that there is a spectrum of NCI pathology in the limbic regions and that atypical MSA is an extreme variant of MSA-CI.
Nevertheless, the present study could not identify the regions responsible for specific cognitive deficits. Deficits in processing speed and executive functions are considered to be caused by deep white matter damage including periventricular, cingulate, and frontal white matter. [33] [34] [35] [36] We selected deep white matter under the cingulate gyrus and middle frontal gyrus to assess this pathology, but there was no difference in the burden of GCI. On the other hand, Cykowski et al reported a significant association between Lewy body-like NCIs in the neocortex and CI. 5 We identified Lewy body-like NCIs in only 2 patients, and they were cognitively intact. The frequency of NCIs also differed between the 2 studies. We found this pathology in 68% of patients, whereas all 35 patients had NCIs in the superior frontal gyrus in their study. This discrepancy might be caused by different regions of interest (middle frontal vs superior frontal), technical issues (ie, a-synuclein immunohistochemistry), and morphologic criteria for NCIs. It is challenging to distinguish between genuine Lewy bodies from Lewy body-like NCIs in MSA, 37 ,38 but we considered the pathology in these 2 patients to be NCI, not Lewy body, because there were no Lewy bodies and Lewy neurites in the regions most frequently affected in Lewy body disease such as the dorsal motor nucleus of the vagus nerve and locus coeruleus. 39 In addition to NCIs, overall progression of the underlying pathology including a-synuclein, neuronal loss, and synaptic loss, could be associated with CI. Further studies are necessary to elucidate the pathological mechanism of CI in MSA.
A major limitation of our study is its retrospective nature and that not all patients with MSA received cognitive screening tests or neuropsychological evaluations. Only 27% of patients with MSA-CI underwent a formal neuropsychological assessment, with 50% receiving an objective measure of cognitive functioning overall. Diagnosis of cognitively intact patients is another challenge. Sixty-nine patients were considered cognitively intact based on a review of records involving physician examinations. It should be noted that because of the retrospective record review design of this study, only CI reported in patient records was available for analysis. This inclusion of only explicitly positive or negative findings might cause an underestimation of CI in MSA. Therefore, prospective studies collecting detailed symptom profiles and severity indicators are required to Data are displayed as median (25th, 75th percentiles).
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obtain a more accurate understanding of CI in MSA. Another limitation is a method to assess white matter pathology. We only sampled 2 areas (ie, deep white matter under the cingulate gyrus and middle frontal gyrus) to assess a correlation between white matter pathology and CI, but it should be evaluated in more regions, including periventricular white matter. In addition, GCI scores might be underestimated because of the ceiling effect; most cases have a score of 2 or 3 of the 4-point scale. A notable strength of our study is that diagnoses of MSA were confirmed at autopsy, whereas most of the literature on CI in MSA is based on clinical MSA. Because the clinical diagnostic accuracy of MSA is only 62%, 6 it is important to study MSA based on autopsyconfirmed cohorts. Another advantage of this study is the size of the sample with autopsy-confirmed MSA reviewed for CI, which is greater than in previously published studies. 5, 9 In conclusion, the results of our study show that a subset of patients with MSA have mild cognitive deficits primarily in processing speed and attention/executive functions, which suggests a predominant frontalsubcortical pattern of cognitive dysfunction. When assessed objectively, these deficits were more evident on neuropsychological assessment compared with cognitive screens, which tend to be limited in the measurement of processing speed and executive functions. Our findings suggest that clinicians should be aware that subjective CI in MSA primarily presents subjectively as memory complaints, which are not substantiated on neuropsychological tests. Furthermore, we recommend that clinicians consider neuropsychological assessment beyond cognitive screening instruments if patients with MSA present with cognitive complaints. Although we did not identify a correlation between the domains of CI and respective functional neuroanatomical regions, a greater burden of NCI in the dentate gyrus was associated with CI in MSA.
